Physician profile
Martin Johnson
NPI 1225023773
$3,171.04
in general payments reported to CMS, 2019-2025
15 companies · $609 in 2025
The $609 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $165 · 2021: $410 · 2022: $504 · 2023: $397 · 2024: $707 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,712.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $968.32 | 2020-2025 | Otezla, Otezla |
| Abbvie INC. | $420.70 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $317.82 | 2019-2025 | |
| Lilly USA, LLC | $273.25 | 2019-2024 | Taltz, Olumiant |
| Janssen Biotech, INC. | $260.89 | 2019-2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $247.38 | 2022-2025 | Ilumya |
| Galderma Laboratories, L.P. | $152.39 | 2021-2025 | Nemluvio |
| Ucb, INC. | $149.11 | 2025 | Bimzelx |
| Celgene Corporation | $120.05 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $65.66 | 2022-2024 | Sotyktu |
| Blueprint Medicines Corporation | $60.09 | 2025 | Ayvakit |
| Dermavant Sciences, INC. | $42.81 | 2023 | Vtama |
| Genzyme Corporation | $38.91 | 2019-2021 | |
| Pfizer INC. | $36.55 | 2019-2022 | |
| Leo Pharma INC. | $17.11 | 2024 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.